Status:
COMPLETED
Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma
Lead Sponsor:
Ohio State University Comprehensive Cancer Center
Conditions:
Oligoastrocytoma, Mixed
Anaplastic Oligodendroglioma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Rationale: Standard therapy for anaplastic oligodendrogliomas and mixed oligoastrocytomas includes radiation and chemotherapy. However, due to the potential long-term central nervous system toxicity ...
Detailed Description
Temozolomide has demonstrated clinical antitumor efficacy against malignant gliomas at both relapse and initial diagnosis. This drug appears to have less adverse effects compared to other drugs used a...
Eligibility Criteria
Inclusion
- anaplastic oligodendroglioma or mixed oligoastrocytoma
- age \> 18
- Karnofsky status \> 70%
- adequate bone marrow, liver and renal function
Exclusion
- prior chemotherapy or cranial irradiation
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT00362570
Start Date
May 1 2005
End Date
March 1 2011
Last Update
November 30 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ohio State University
Columbus, Ohio, United States, 43210